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An intensified perfusion process for production of a therapeutic monoclonal antibody was developed and scaled 
to 100 L clinical and 500 L commercial scales.  The baseline process was developed in 10 L benchtop 
bioreactors with stainless steel alternating tangential flow (ATF) cell retention systems.  The process consisted 
of a 12 day growth phase followed by a 48 day harvest phase.  Cell densities of >120 Mvc/mL were sustained 
with high culture viability.  Productivities of >3 g/L·d were maintained throughout the harvest phase.  The 
process was successfully scaled up to a 100 L single use bioreactor with dual ATF6 filters for clinical 
manufacturing.  To verify that the process would perform similarly at commercial manufacturing scale, a proof of 
concept run was conducted in a 500 L single use bioreactor with dual ATF10 filters.  Biomass concentration, 
culture viability, and productivity were comparable across scales.  A full 60 day campaign in a 500 L bioreactor 
would generate over 70 kg of product in the clarified harvest.  These studies demonstrate that intensified 
perfusion processes developed in benchtop bioreactors can be successfully reproduced at scales relevant for 
manufacturing. 
 
 
